Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI plus durvalumab with or without tremelimumab in second-line advanced gastric or gastro-oesophageal junction adenocarcinoma
2018-002014-13Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Oct 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing FOLFIRI + durvalumab with FOLFIRI + durvalumab + tremelimumab (2 arms). Primary endpoint: Percentage of patients alive and without radiological progression at 4 months according to investigator. Started Oct 2018; status: completed.
02
Drugs
durvalumabtremelimumabFOLFIRI
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-002014-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002014-13.